


## EFFICIENT NEW SYNTHESSES OF BENZOCHLORINS, BENZOISOBACTERIOCHLORINS, AND BENZOBACTERIOCHLORINS

M. Graça H. Vicente, Irene N. Rezzano, and Kevin M. Smith\*

Department of Chemistry, University of California, Davis, California 95616

**Abstract:** Reaction of nickel(II) or copper(II) porphyrins with 3-dimethylamino-acrolein/ $\text{POCl}_3$  gives meso-(2-formylvinyl)-porphyrins, which after strong acid treatment give the corresponding benzochlorins. Use of nickel(II) or copper(II) chlorins gives benzoisobacteriochlorins; a modification also gives benzobacteriochlorins. Reductive coupling of (2-formylvinyl) derivatives gives carbon-carbon linked dimers.

PHOTOFRIN-II® is the only drug currently being evaluated in phase III clinical trials for treatment of various tumors using photodynamic therapy (PDT). It is a purified form of "hematoporphyrin derivative" prepared from hematoporphyrin IX dihydrochloride in two steps by modifications of Lipson's procedure.<sup>1</sup> Photofrin-II® is a complex mixture of porphyrins, believed to be porphyrin dimers and higher oligomers joined by ether, ester, and/or carbon-carbon linkages, and chemical syntheses of all of these types of linked dimers and oligomers have recently been reported.<sup>2-7</sup> Amongst numerous other sensitizers for PDT,<sup>8-10</sup> purpurins<sup>9</sup> and benzochlorins<sup>10</sup> have shown promise. We now outline a new route to benzochlorins using procedures applicable also to purpurin synthesis, and show that intermediates in these approaches can be used to furnish carbon-carbon linked porphyrin dimers related to one of the active principles<sup>7</sup> in Photofrin-II®.




- (1) R = H; M = Ni  
(2) R = H; M = Cu  
(3) R = CH=CH-CHO; M = Ni  
(4) R = CH=CH-CHO; M = Cu  
(5) R = H; M = Ni  
(6) R = H; M = Cu  
(8) R = CH=CH-CHO; M = Ni

(7)


Both nickel(II) octaethylporphyrin (1; NiOEP) and CuOEP (2) reacted with 3-dimethylamino-acrolein (3-DMA) in the presence of phosphoryl chloride<sup>11</sup> to give 85% yield of Ni meso-(2-formylvinyl)-OEP (3)<sup>12a</sup> and 57% of Cu meso-(2-formylvinyl)-OEP (4), respectively. When treated with strong acids (trifluoroacetic and sulfuric) the acrolein group at the meso positions cyclized onto the pyrrole subunit  $\beta$ -position with concomitant alkyl migration, to give Ni octaethylbenzochlorin (5)<sup>12b</sup> and Cu octaethylbenzochlorin (6) in 50% and 80% yields, respectively.<sup>13</sup> The free-base

octaethylbenzochlorin (7)<sup>12c</sup> was prepared in 80% yield from sulfuric acid treatment of (6) [or in 10% yield from (5) with trifluoroacetic acid and 1,3-propanedithiol].<sup>14</sup> Further treatment of the Ni octaethylbenzochlorin (5) with 3-DMA/phosphoryl chloride gave compound (8)<sup>12d</sup> in 85% yield; the benzochlorin reacted faster than (1) and gave (8) as the only regioisomer. With acid, compound (8) gave the benzoisobacteriochlorin (9)<sup>12e</sup>.




When exposed to a large excess of the Vilsmeier complex from 3-DMA and phosphoryl chloride, NiOEP (1) gave the Ni bis(2-formylvinyl)-OEP (10)<sup>12f</sup> in 55% yield. Upon acid treatment, this compound yielded several products, but mainly the benzoisobacteriochlorin (9) and the benzobacteriochlorin (11)<sup>12g</sup>.

In order to investigate the relative reactivities of meso- versus pyrrolic unsubstituted positions, Ni deuteroporphyrin-IX dimethyl ester (12) was treated with 3-DMA/phosphoryl chloride and gave a mixture of products containing the acrolein group only at the meso positions, and in accord with expectations from previous Vilsmeier formylation studies,<sup>15</sup> mostly at the  $\beta$ -meso-position. Upon acid catalyzed cyclization, the readily separable benzochlorins (13)(metal-free)<sup>12h</sup> and (14)<sup>12i</sup> were produced. A compound similar to (13) has previously been prepared by Clezy et al.<sup>16</sup> from oxidation of rhodins.




Using this same chemistry, benzoisobacteriochlorins can be easily formed by the reaction of natural chlorins with 3-DMA/phosphoryl chloride. For example, Ni mesochlorin-e<sub>6</sub> trimethyl ester (15) gave Ni  $\delta$ -(2-formylvinyl)-mesochlorin-e<sub>6</sub> trimethyl ester (16)<sup>12j</sup> in 89% yield. Under strong acid conditions compound (16) gave the benzoisobacteriochlorin (17)<sup>12k</sup> in 55% yield.

In order for the cyclization step to occur strong acid conditions are required (usually concentrated sulfuric acid from 15 min to 2.5 h), along with a centrally chelated metal to prevent protonation from curtailing the electrophilic cyclization of the meso-substituent to the pyrrolic  $\beta$ -position. If the metal is removed before cyclization occurs then the benzochlorins and benzoisobacteriochlorins cannot be formed. As a demonstration of this chemistry, although methyl Ni meso-(2-formylvinyl)-mesopyropheophorbide-a (18)<sup>12l</sup> was easily prepared from methyl Ni-mesopyropheophorbide-a (19) in 83% yield, the metal was rapidly extruded during the acidic cyclization step and only methyl meso-(2-formylvinyl)-mesopyropheophorbide-a (20)<sup>12m</sup> was obtained instead. Unlike the usual Vilsmeier reagent from DMF/POCl<sub>3</sub>, the 3-DMA reagent does not react with peripheral vinyl groups in porphyrins and chlorins.<sup>15a</sup>



As mentioned above, carbon-carbon linked dimers of porphyrins are important in photodynamic therapy because of their activity as components in Photofrin-II®. Using the chemistry demonstrated above, chlorins and benzochlorins can be prepared by the reductive coupling of the aldehyde function of the acrolein group, using low-valent titanium.<sup>17</sup> Dimers like compound (21)<sup>12n</sup> were prepared by the reaction of Ni (2-formylvinyl)-OEP (3) with TiCl<sub>3</sub>(DME)<sub>1.5</sub> in the presence of a zinc-copper couple. Usefulness of such dimers in photodynamic therapy will be reported elsewhere.



**Acknowledgments:** We thank the National Institutes of Health (HL 22252) and the National Science Foundation (CHE-86-19034) for support of this research.

#### References and Notes

1. R.L. Lipson, E.J. Baldes, and A.M. Olsen, *J. Natl. Cancer Inst.*, **1961**, *26*, 1.
2. I.K. Morris and A.D. Ward, *Tetrahedron Lett.*, **1988**, *29*, 2501.

3. R.K. Pandey, T.J. Dougherty, and K.M. Smith, *Tetrahedron Lett.*, **1988**, *29*, 4657.
4. R.K. Pandey and T.J. Dougherty, *Cancer Res.*, **1989**, *49*, 2042.
5. R.K. Pandey, K.M. Smith, and T.J. Dougherty, *J. Med. Chem.*, in press.
6. R.K. Pandey and T.J. Dougherty, *Photochem. Photobiol.*, **1988**, *47*, 769.
7. R.K. Pandey, F.-Y. Shiau, T.J. Dougherty, and K.M. Smith, submitted for publication.
8. R.K. Pandey, D.A. Majchrzycki, K.M. Smith, and T.J. Dougherty, *SPIE Proc.*, **1989**, *1065*, 164.
9. A.R. Morgan and N.C. Tertel, *J. Org. Chem.*, **1986**, *51*, 1347.
10. A.R. Morgan, V.S. Pangka, and D. Dolphin, *J. Chem. Soc., Chem. Commun.*, **1984**, 1047. A.M. Richter, B. Kelly, J. Chow, D.J. Liu, G.H.N. Powers, D. Dolphin, and J.G. Levy, *J. Natl. Cancer Inst.*, **1987**, *79*, 1327.
11. M. Gosmann and B. Franck, *Angew. Chem. Int. Edn. Engl.*, **1986**, *25*, 1100.
12. Characteristic spectroscopic data: (a) (3)Vis:  $\lambda_{\max}$  406 ( $\epsilon$  70 800), 536 (15 900), 564 (17 900), 582 nm (17 200); NMR  $\delta_{\text{H}}$  9.84 (d, CHO,  $J=7.7$  Hz), 9.69 (d,  $\text{CH}=\text{CHCHO}$ ,  $J=15.2$  Hz), 9.36 (s, 3 meso-H), 5.53 (dd,  $\text{CH}=\text{CHCHO}$ ); (b) (5)Vis:  $\lambda_{\max}$  373 ( $\epsilon$  14 300), 414 (37 100), 508 (4 600), 564 (4 200), 618 (6 800), 670 nm (20 000); NMR  $\delta_{\text{H}}$  8.98 (d, Ar-H), 8.89, 8.54 and 7.83 (s, 3 meso-H), 7.82 (d, Ar-H), 7.79 (t, Ar-H); (c) (7)Vis:  $\lambda_{\max}$  392 ( $\epsilon$  87 200), 412 (107 500), 530 (13 750), 564 (15 400), 604 (17 000), 658 nm (35 000); NMR,  $\delta_{\text{H}}$  9.23, 8.57, 8.01 (each s, 3 meso-H), 9.54 (d, 1 Ar-H,  $J=8.1$  Hz), 8.12 (t, 1 Ar-H,  $J=7.8$  Hz), 8.04 (d, 1 Ar-H,  $J=7.6$  Hz); (d) (8)Vis:  $\lambda_{\max}$  376 ( $\epsilon$  46 700), 444 (70 500), 726 nm (47 900); NMR,  $\delta_{\text{H}}$  9.68 (d, CHO,  $J=7.8$  Hz), 8.69 (d,  $\text{CH}=\text{CHCHO}$ ,  $J=15.0$  Hz), 8.63 (d, Ar-H,  $J=8.1$  Hz), 8.49, 8.21 (s, 2 meso-H), 7.70 (t, 1 Ar-H), 7.63 (d, 1 Ar-H), 5.72 (dd,  $\text{CH}=\text{CHCHO}$ ); (e) (9)Vis:  $\lambda_{\max}$  340 ( $\epsilon$  37 000), 444 (45 600), 634 nm (38 600); (f) (10)Vis:  $\lambda_{\max}$  338 ( $\epsilon$  58 800), 458 (156 700), 616 nm (29 900); NMR  $\delta_{\text{H}}$  9.87 (d, 2 CHO,  $J=7.8$  Hz), 9.56 (d, 2H,  $\text{CH}=\text{CHCHO}$ ,  $J=15.3$  Hz), 9.14 (s, 2 meso-H), 5.58 (dd, 2H,  $\text{CH}=\text{CHCHO}$ ); (g) (11)Vis:  $\lambda_{\max}$  352 ( $\epsilon$  38 200), 384 (41 000), 402 (45 200), 452 (44 000), 644 (18 500), 686 (19 500), 752 nm (41 800); (h) (13)Vis:  $\lambda_{\max}$  331 ( $\epsilon$  17 700), 410 (56 200), 538 (7 150), 572 (8 200), 614 (8 100), 670 nm (17 500); NMR  $\delta_{\text{H}}$  9.45 (d, 1 Ar-H,  $J=8.4$  Hz), 9.12, 8.63 and 8.27 (s, 3 meso-H), 8.24 (d, 1 Ar-H,  $J=6.9$  Hz), 8.19 (s, 1  $\beta$ -H), 7.98 (t, 1 Ar-H,  $J=7.5$  Hz); (i) (14)Vis:  $\lambda_{\max}$  305 ( $\epsilon$  10 600), 412 (51 000), 508 (4 000), 564 (3 400), 616 (7 250), 668 nm (26 160); NMR  $\delta_{\text{H}}$  8.97 (d, 1 Ar-H,  $J=8.6$  Hz), 8.88, 8.57 and 7.94 (s, 3 meso-H), 8.24 and 8.18 (s, 2  $\beta$ -H), 7.86 (m, 2 Ar-H); (j) (16)Vis:  $\lambda_{\max}$  428 ( $\epsilon$  99 800), 574 (15 950), 582 (15 650), 672 nm (42 150); NMR  $\delta_{\text{H}}$  9.69 (d, CHO,  $J=7.8$  Hz), 8.72 and 8.62 (s, 2 meso-H), 8.36 (d,  $\text{CH}=\text{CHCHO}$ ,  $J=15.4$  Hz), 5.72 (dd,  $\text{CH}=\text{CHCHO}$ ); (k) (17)Vis:  $\lambda_{\max}$  354 ( $\epsilon$  23 300), 432 (57 000), 602 nm (32 100); NMR  $\delta_{\text{H}}$  8.06 (d, Ar-H  $J=8.4$  Hz), 7.98, 6.99 (s, 2 meso-H), 7.58 (d, Ar-H,  $J=6.6$  Hz), 7.44 (t, Ar-H,  $J=7.5$  Hz); (l) (18)Vis:  $\lambda_{\max}$  430 ( $\epsilon$  46 850), 682 (26 600), 752 nm (7 800); NMR  $\delta_{\text{H}}$  9.79 (d, CHO,  $J=7.8$  Hz), 8.96 and 8.67 (s, 2 meso-H), 8.49 (d,  $\text{CH}=\text{CHCHO}$ ,  $J=15.3$  Hz), 5.83 (dd,  $\text{CH}=\text{CHCHO}$ ); (m) (20) Vis:  $\lambda_{\max}$  414 ( $\epsilon$  118 000), 564 (17 800), 620 (11 000), 680 nm (26 900); NMR  $\delta_{\text{H}}$  10.10 (d, CHO,  $J=7.8$  Hz), 9.40, 9.33 (s, 2 meso-H), 9.12 (d,  $\text{CH}=\text{CHCHO}$ ,  $J=15.6$  Hz), 6.57 (dd,  $\text{CH}=\text{CHCHO}$ ); (n) (21) Vis:  $\lambda_{\max}$  404 ( $\epsilon$  101 300), 562 nm (26 800); NMR  $\delta_{\text{H}}$  9.37 (s, 6 meso-H), 8.64 (d, 2 vinyl-H), 6.41 (dd, 2 vinyl-H), 5.41 and 5.48 (both dd, 2 vinyl-H).
13. Compound (5) has been obtained by a much lengthier approach involving Vilsmeier formylation, Knoevenagel condensation, reduction, oxidation, and cyclization (D.P. Arnold, R. Gaete-Holmes, A.W. Johnson, A.R.P. Smith, and G.A. Williams, *J. Chem. Soc., Perkin Trans. I*, **1978**, 1660.) Purpurins are also synthesized from cyclization of the corresponding meso-acrylic porphyrins after the Knoevenagel step.<sup>9</sup>
14. An X-ray structure of compound (7) has been obtained: K.M. Barkigia, J. Fajer, M.G.H. Vicente, and K.M. Smith, to be published.
15. (a) A.W. Nichol, *J. Chem. Soc. C*, **1970**, 903. (b) K.M. Smith and K.C. Langry, *J. Chem. Soc., Perkin Trans. I*, **1983**, 439.
16. P.S. Clezy, A.H. Mirza, B.N. Ravi, and L. v. Thuc, *Aust. J. Chem.*, **1984**, *37*, 143.
17. J.E. McMurry, T. Lectka, and J.G. Rico, *J. Org. Chem.*, **1989**, *54*, 3748.